Protagenic Therapeutics (PTIX) Competitors $0.24 -0.02 (-6.65%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.23 -0.01 (-4.13%) As of 04/17/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PTIX vs. CSCI, AFMD, BMRA, CTXR, GOVX, GELS, IXHL, APRE, RLMD, and TLPHShould you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include COSCIENS Biopharma (CSCI), Affimed (AFMD), Biomerica (BMRA), Citius Pharmaceuticals (CTXR), GeoVax Labs (GOVX), Gelteq (GELS), Incannex Healthcare (IXHL), Aprea Therapeutics (APRE), Relmada Therapeutics (RLMD), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry. Protagenic Therapeutics vs. COSCIENS Biopharma Affimed Biomerica Citius Pharmaceuticals GeoVax Labs Gelteq Incannex Healthcare Aprea Therapeutics Relmada Therapeutics Talphera Protagenic Therapeutics (NASDAQ:PTIX) and COSCIENS Biopharma (NASDAQ:CSCI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations. Which has better valuation and earnings, PTIX or CSCI? Protagenic Therapeutics has higher earnings, but lower revenue than COSCIENS Biopharma. COSCIENS Biopharma is trading at a lower price-to-earnings ratio than Protagenic Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagenic TherapeuticsN/AN/A-$5M-$1.13-0.21COSCIENS Biopharma$9.59M0.96-$16.55M-$9.38-0.31 Which has more volatility & risk, PTIX or CSCI? Protagenic Therapeutics has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, COSCIENS Biopharma has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Does the media favor PTIX or CSCI? In the previous week, COSCIENS Biopharma had 3 more articles in the media than Protagenic Therapeutics. MarketBeat recorded 4 mentions for COSCIENS Biopharma and 1 mentions for Protagenic Therapeutics. Protagenic Therapeutics' average media sentiment score of 1.00 beat COSCIENS Biopharma's score of 0.41 indicating that Protagenic Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Protagenic Therapeutics Positive COSCIENS Biopharma Neutral Do institutionals & insiders have more ownership in PTIX or CSCI? 8.0% of Protagenic Therapeutics shares are held by institutional investors. Comparatively, 0.7% of COSCIENS Biopharma shares are held by institutional investors. 35.0% of Protagenic Therapeutics shares are held by company insiders. Comparatively, 0.1% of COSCIENS Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is PTIX or CSCI more profitable? Protagenic Therapeutics has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -428.43%. COSCIENS Biopharma's return on equity of -95.93% beat Protagenic Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protagenic TherapeuticsN/A -308.97% -228.73% COSCIENS Biopharma -428.43%-95.93%-45.66% Does the MarketBeat Community prefer PTIX or CSCI? Protagenic Therapeutics and COSCIENS Biopharma both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformProtagenic TherapeuticsN/AN/ACOSCIENS BiopharmaN/AN/A SummaryProtagenic Therapeutics beats COSCIENS Biopharma on 7 of the 12 factors compared between the two stocks. Get Protagenic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTIX vs. The Competition Export to ExcelMetricProtagenic TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.81M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.196.8921.8017.80Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.295.936.443.98Net Income-$5M$142.99M$3.21B$247.73M7 Day Performance-20.03%4.42%2.87%1.81%1 Month Performance-7.66%-12.73%-8.63%-6.98%1 Year Performance-82.49%-9.48%11.46%1.37% Protagenic Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIXProtagenic Therapeutics1.5667 of 5 stars$0.24-6.7%N/A-82.2%$1.81MN/A-0.192Short Interest ↓Positive NewsGap DownCSCICOSCIENS BiopharmaN/A$2.44-4.7%N/AN/A$9.21M$7.60M-0.2120AFMDAffimed3.5306 of 5 stars$0.57flat$13.50+2,268.0%-86.0%$9.18M$877,000.000.00200Analyst ForecastGap UpBMRABiomerica0.2299 of 5 stars$0.50-0.4%N/A-36.1%$9.13M$5.58M-1.4660Earnings ReportStock SplitShort Interest ↑News CoverageGap UpCTXRCitius Pharmaceuticals2.1861 of 5 stars$1.05+3.4%$54.50+5,090.5%-95.3%$9.02MN/A0.0020Short Interest ↑GOVXGeoVax Labs2.3206 of 5 stars$0.95-6.7%$14.20+1,391.4%-43.2%$8.98M$3.95M-0.1710Analyst ForecastShort Interest ↑Analyst RevisionGELSGelteqN/A$0.94+4.4%N/AN/A$8.87MN/A0.00N/ANews CoverageGap UpIXHLIncannex Healthcare0.6545 of 5 stars$0.49-5.2%N/A-74.8%$8.81M$98,000.00-0.353Gap DownAPREAprea Therapeutics2.55 of 5 stars$1.59-6.5%$15.50+874.8%-73.8%$8.73M$580,000.00-0.577Gap DownRLMDRelmada Therapeutics3.3357 of 5 stars$0.26-4.5%$4.25+1,534.0%-93.8%$8.63MN/A-0.0910TLPHTalphera2.8801 of 5 stars$0.50-1.7%$4.33+763.2%-52.4%$8.58M$281,000.00-0.7319Short Interest ↓Gap Down Related Companies and Tools Related Companies COSCIENS Biopharma Alternatives Affimed Alternatives Biomerica Alternatives Citius Pharmaceuticals Alternatives GeoVax Labs Alternatives Gelteq Alternatives Incannex Healthcare Alternatives Aprea Therapeutics Alternatives Relmada Therapeutics Alternatives Talphera Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTIX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTIX Stock Free PTIX Stock Alerts